GlaxoSmithKline plc (LON:GSK) dropped 0.9% on Tuesday . The company traded as low as GBX 1,277.83 ($17.20) and last traded at GBX 1,279 ($17.21). Approximately 10,619,741 shares traded hands during mid-day trading, a decline of 9% from the average daily volume of 11,650,000 shares. The stock had previously closed at GBX 1,290.50 ($17.37).
GSK has been the topic of a number of recent analyst reports. Societe Generale reiterated a “sell” rating on shares of GlaxoSmithKline in a research report on Thursday, November 9th. Berenberg Bank cut their price objective on GlaxoSmithKline from GBX 1,835 ($24.70) to GBX 1,760 ($23.69) and set a “buy” rating on the stock in a research report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($19.52) price objective on GlaxoSmithKline and gave the stock a “sell” rating in a research report on Monday, November 6th. Deutsche Bank set a GBX 1,610 ($21.67) price objective on GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Friday, October 27th. Finally, Barclays restated an “equal weight” rating and issued a GBX 1,450 ($19.52) target price on shares of GlaxoSmithKline in a research note on Friday, October 27th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 1,577.14 ($21.23).
GlaxoSmithKline (LON:GSK) last announced its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.
In other GlaxoSmithKline news, insider Urs Rohner purchased 473 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The stock was purchased at an average price of GBX 1,518 ($20.43) per share, for a total transaction of £7,180.14 ($9,663.71). Also, insider Simon Dingemans purchased 1,076 shares of the firm’s stock in a transaction dated Thursday, October 12th. The stock was acquired at an average price of GBX 1,527 ($20.55) per share, with a total value of £16,430.52 ($22,113.76). Insiders have acquired 1,576 shares of company stock valued at $2,400,376 in the last quarter.
TRADEMARK VIOLATION WARNING: This story was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/12/07/glaxosmithkline-gsk-shares-down-0-9.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.